As discussed in Section 2 and summarized in Table 2, there are clear clinical benefits in using the PARPi to treat BRCA1/2 mutated ovarian, breast, prostate, and pancreatic cancers, however, they are not a panacea for all the aforementioned malignancies. The gene discussed is BRCA1; the disease is pancreatic neoplasm.